286PFirst china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). (25th November 2018) - Shi, Y; Zhang, Q; Han, X; Song, Y; Qin, Y; Hong, X; Ke, X; Feng, J; Wang, D; Li, W; Su, H; Zhang, Y; et al.